Peptide and Small Molecule Inhibitors Targeting Myeloid Cell Leukemia 1 (Mcl-1) as Novel Antitumor Agents

Curr Mol Med. 2021;21(5):426-439. doi: 10.2174/1566524020666200929121016.

Abstract

Myeloid cell leukemia 1 (Mcl-1) is a member of the Bcl-2 family of proteins with anti-apoptotic activity. It plays a key role in the regulation of the intrinsic pathway of apoptosis. Moreover, Mcl-1 is correlated with the progression and drug-resistance of various cancers. The development of inhibitors of Mcl-1 may provide effective cancer therapies. While the inhibitors of other Bcl-2 anti-apoptotic proteins have been well explored, the discovery of Mcl-1inhibitors with high selectivity has been challenging. In this review, we summarize the recent literature on small molecule and peptide inhibitors of Mcl-1, which are divided into different types including peptide inhibitors, gossypol derivatives, marinopyrrole derivatives, S1 derivatives, indole derivatives, quinoline derivatives, S63845, AZD5991, AMG176, etc. Their biological activities are also summarized. Mcl-1 is a valid drug target and inhibition of Mcl-1 with a small molecule inhibitor is a promising strategy for cancer therapy.

Keywords: Anti-apoptotic proteins; Antitumor agents; Apoptosis; Bcl-2 family proteins; Myeloid cell leukemia 1 inhibitor..

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Apoptosis / drug effects
  • Humans
  • Leukemia / drug therapy*
  • Myeloid Cells / drug effects*
  • Peptides / therapeutic use*
  • Small Molecule Libraries / therapeutic use*

Substances

  • Antineoplastic Agents
  • Peptides
  • Small Molecule Libraries